Novo Nordisk and China's United Laboratories have announced positive Phase II results for their triple agonist, UBT251, in a Chinese population with overweight or obesity. The study evaluated weekly subcutaneous injections of UBT251 (2mg, 4mg, 6mg) against a placebo. After 24 weeks of treatment, the highest dose group achieved a mean weight reduction of 19.7% (17.5 kg) from baseline, compared to a 2.0% reduction in the placebo group. The candidate also showed statistically significant improvements in key secondary metabolic parameters.

UBT251, a long-acting GLP-1/GIP/GCGR triple agonist developed by United Labs' subsidiary Federal Biotechnology, was licensed to Novo for overseas markets in March 2025. The drug was well-tolerated, with the most common adverse events being mild-to-moderate gastrointestinal side effects typical of incretin-based therapies. Based on these results, United Labs plans to initiate a Phase III trial in China, while Novo is progressing a global Phase Ib/IIa study and planning a Phase II trial for type 2 diabetes.

According to PharmCube's NextBiopharm® database, UBT251 ranks third globally in terms of development among GLP-1/GIP/GCGR triple agonists. Click here to request a free trial for NextBiopharm®.